Trial Profile
A retrospective study evaluating discontinuation patterns of Non-Vitamin K Antagonist Oral Anticoagulants in the first year of therapy in patients with non-valvular atrial fibrillation in UK general practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jan 2020
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Stroke
- Focus Therapeutic Use
- 12 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association